551
Participants
Start Date
September 30, 2015
Primary Completion Date
April 30, 2017
Study Completion Date
May 31, 2017
lefamulin
antibacterial agent
Moxifloxacin
antibacterial agent
Linezolid
antibacterial agent
Site 5104, Pretoria
Site 5105, Thabazimbi
Site 2003, Manila
Site 2004, Manila
Site 5101, Middelburg
Site 2002, Quezon City
Site 2001, Quezon City
Site 4305, Budapest
Site 4102, Sofia
Site 4101, Sofia
Site 4106, Sofia
Site 5103, Benoni
Site 4110, Sofia
Site 4111, Sofia
Site 5102, Krugersdorp
Site 3005, La Plata
Site 4303, Törökbálint
Site 4112, Pernik
Site 4307, Miskolc
Site 4308, Miskolc
Site 4109, Vidin
Site 4304, Debrecen
Site 4108, Smolyan
Site 4104, Veliko Tarnovo
Site 2005, Iloilo City
Site 4105, Gabrovo
Site 4107, Lovech
Site 4103, Rousse
Site 4302, Farkasgyepű
Site 4306, Csorna
Site 5206, Zhytomyr
Site 2103, Nonthaburi
Site 5002, Belgrade
Site 5004, Kamenitz
Site 5003, Niš
Site 4801, Bucharest
Site 4806, Bucharest
Site 5001, Kragujevac
Site 5208, Sumy
Site 1006, Hazard
Site 1009, Akron
Site 1002, Dayton
Site 1005, Minneapolis
Site 5203, Chernivtsi
Site 1001, Butte
Site 5201, Kharkiv
Site 5211, Odesa
Site 5212, Zaporizhzhia
Site 5210, Zaporizhzhia
Site 1008, Shreveport
Site 4004, Zenica
Site 5209, Kherson
Site 4001, Tuzla
Site 5204, Ivano-Frankivsk
Site 1004, Splendora
Site 4003, Mostar
Site 4905, Yaroslavl
Site 4903, Saint Petersburg
Site 4901, Saint Petersburg
Site 4803, Craiova
Site 4808, Craiova
Site 4906, Smolensk
Site 4807, Timișoara
Site 4809, Timișoara
Site 4904, Chelyabinsk
Site 4902, Novosibirsk
Site 4802, Palazu Mare
Site 3006, Rosario
Site 3003, Córdoba
Site 3007, Córdoba
Site 3001, Córdoba
Site 3004, Córdoba
Site 3104, Belo Horizonte
Site 3102, Passo Fundo
Site 3103, Campinas
Site 3101, Sao Paulo Do Rio Preto
Site 4206, Tbilisi
Site 4204, Tbilisi
Site 4205, Tbilisi
Site 4201, Tbilisi
Site 4202, Tbilisi
Site 4403, Daugavpils
Site 4401, Liepāja
Site 4402, Riga
Site 4603, Almelo
Site 4602, Helmond
Site 3205, Trujillo
Site 3202, Lima
Site 3204, Lima
Site 3201, Lima
Site 4703, Skierniewice
Site 4704, Warsaw
Site 4701, Lódz
Site 4702, Wilkowice
Site 4810, Bucharest
Site 4811, Cluj-Napoca
Site 5207, Kiyiv
Site 5205, Kyiv
Site 5202, Kyiv
Lead Sponsor
Nabriva Therapeutics AG
INDUSTRY